Gamco Investors INC. ET AL Sells 3,757 Shares of Cigna Group $CI

Gamco Investors INC. ET AL lowered its stake in Cigna Group (NYSE:CI) by 28.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 9,638 shares of the health services provider’s stock after selling 3,757 shares during the period. Gamco Investors INC. ET AL’s holdings in Cigna Group were worth $2,653,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. RiverFront Investment Group LLC bought a new stake in shares of Cigna Group in the fourth quarter valued at about $779,000. North Dakota State Investment Board bought a new position in shares of Cigna Group during the fourth quarter worth about $2,486,000. Rossmore Private Capital grew its holdings in shares of Cigna Group by 51.5% during the fourth quarter. Rossmore Private Capital now owns 4,367 shares of the health services provider’s stock worth $1,202,000 after buying an additional 1,485 shares in the last quarter. Abacus Wealth Partners LLC bought a new position in shares of Cigna Group during the fourth quarter worth about $1,229,000. Finally, Soltis Investment Advisors LLC grew its holdings in shares of Cigna Group by 7.0% during the fourth quarter. Soltis Investment Advisors LLC now owns 3,251 shares of the health services provider’s stock worth $895,000 after buying an additional 212 shares in the last quarter. Institutional investors own 86.99% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CI. Barclays increased their price objective on Cigna Group from $303.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. Truist Financial increased their target price on shares of Cigna Group from $320.00 to $350.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. The Goldman Sachs Group increased their target price on shares of Cigna Group from $335.00 to $340.00 and gave the stock a “buy” rating in a report on Monday, May 4th. Wells Fargo & Company increased their target price on shares of Cigna Group from $300.00 to $305.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Finally, Morgan Stanley increased their target price on shares of Cigna Group from $355.00 to $361.00 and gave the stock an “overweight” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $338.55.

Insiders Place Their Bets

In other news, insider Everett Neville sold 1,719 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $288.91, for a total value of $496,636.29. Following the transaction, the insider directly owned 5,670 shares of the company’s stock, valued at $1,638,119.70. This represents a 23.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Nicole S. Jones sold 2,307 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $288.91, for a total transaction of $666,515.37. Following the completion of the transaction, the insider directly owned 32,647 shares in the company, valued at $9,432,044.77. The trade was a 6.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 205,904 shares of company stock valued at $60,277,068. 0.60% of the stock is currently owned by corporate insiders.

Cigna Group Stock Performance

NYSE CI opened at $283.36 on Thursday. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.69. The firm’s fifty day moving average price is $275.73 and its two-hundred day moving average price is $275.77. Cigna Group has a 1 year low of $239.51 and a 1 year high of $338.89. The firm has a market capitalization of $74.96 billion, a P/E ratio of 12.01, a price-to-earnings-growth ratio of 1.02 and a beta of 0.30.

Cigna Group (NYSE:CI) last posted its quarterly earnings results on Thursday, April 30th. The health services provider reported $7.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.60 by $0.19. Cigna Group had a net margin of 2.26% and a return on equity of 19.75%. The firm had revenue of $68.52 billion for the quarter, compared to analyst estimates of $66.29 billion. During the same period in the prior year, the firm posted $6.74 earnings per share. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. Cigna Group has set its FY 2026 guidance at 30.350- EPS. As a group, research analysts anticipate that Cigna Group will post 30.39 EPS for the current year.

Cigna Group Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Thursday, June 4th will be given a dividend of $1.56 per share. This represents a $6.24 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Thursday, June 4th. Cigna Group’s dividend payout ratio is 26.45%.

Cigna Group Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.